EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial

Masatoshi Kudo, Masafumi Ikeda, Hiroshi Aikata, Kazushi Numata, Hiroyuki Marusawa, Tetsuya Hosaka, Naoya Kato, Masayuki Kurosaki, Manabu Morimoto, Tatsuya Yamashita, Hironori Koga, Tsutomu Masaki und 5 weitere

Liver Cancer · 14.11.2024 · 14 (4) · 365-377

DOI: 10.1159/000542572 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 14.11.2024. Verfasst von Masatoshi Kudo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Kindai University Hospital, Osaka, Japan. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The phase 3 LEAP-002 study (NCT03713593) of advanced hepatocellular carcinoma (HCC) suggested improved antitumor activity of lenvatinib plus pembrolizumab versus lenvatinib alone with manageable safety, although overall survival (OS) and progression-free survival (PFS) did not reach prespecified statistical significance. This post hoc analysis assessed efficacy and safety in Japanese patients.

Methods

Patients with advanced HCC without prior systemic treatment were randomly assigned 1:1 to receive 8 mg (body weight

Schlagwörter

Stichwörter der Autor:innen

Hepatocellular carcinomaJapanLenvatinibPembrolizumabPost hoc analysis

Autor:innen und Institutionen

  • Kindai University Hospital, Osaka, Japan.
  • National Cancer Center Hospital East, Kashiwa, Japan.
  • Hiroshima Prefectural Hospital, Hiroshima, Japan.
  • Yokohama City University Medical Center, Yokohama, Japan.
  • Japanese Red Cross Osaka Hospital, Osaka, Japan.
  • Toranomon Hospital, Tokyo, Japan.

Zitieren

APA

Kudo, M., Ikeda, M., Aikata, H., Numata, K., Marusawa, H., Hosaka, T., Kato, N., Kurosaki, M., Morimoto, M., Yamashita, T., Koga, H., Masaki, T., Yatsuzuka, N., Suzuki, M., Nagao, S., Kaneko, S., & Kumada, H. (2024). First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial. Liver Cancer, 14(4), 365-377. https://doi.org/10.1159/000542572

Vancouver

Kudo M, Ikeda M, Aikata H, Numata K, Marusawa H, Hosaka T, et al. First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial. Liver Cancer. 2024;14(4):365-377. doi:10.1159/000542572

BibTeX
@article{Kudo2024,
  author = {Kudo, Masatoshi and Ikeda, Masafumi and Aikata, Hiroshi and Numata, Kazushi and Marusawa, Hiroyuki and Hosaka, Tetsuya and Kato, Naoya and Kurosaki, Masayuki and Morimoto, Manabu and Yamashita, Tatsuya and Koga, Hironori and Masaki, Tsutomu and Yatsuzuka, Naoyoshi and Suzuki, Masato and Nagao, Satoshi and Kaneko, Shuichi and Kumada, Hiromitsu},
  title = {First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial},
  journal = {Liver Cancer},
  year = {2024},
  volume = {14},
  number = {4},
  pages = {365--377},
  doi = {10.1159/000542572}
}
Kostenlos starten →